Clinical phenotypic spectrum of CTNNB1 neurodevelopmental disorder
Clinical Genetics · 2024-05 · 105 (5) · 523-532
DOI: 10.1111/cge.14487 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Genetics, online erschienen am 21.01.2024. Verfasst von Khemika K Sudnawa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Intellectual Disability, Neurodevelopmental Disorders, Microcephaly. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NIA NIH HHS, CTNNB1 Connect and Cure.
Abstract (Originalsprache)
Pathogenic heterozygous loss of function variants in CTNNB1 are associated with CTNNB1 neurodevelopmental disorder. We report the clinical phenotype of individuals with CTNNB1 neurodevelopmental disorder using both caregiver‐reported data (medical history, adaptive function, quality of life, and behavior issues) and in‐person clinical assessments (neurological, motor, and cognitive function) in 32 individuals with likely pathogenic or pathogenic CTNNB1 variants. Most individuals had truncal hypotonia, muscle weakness, hypertonia, dystonia, microcephaly, and many had a history of tethered cord. Visual problems included strabismus, hyperopia, and familial exudative vitreoretinopathy. Half of individuals walked without an assistive device. The mean Gross Motor Functional Measure‐66 score was 56.6 (SD = 14.8). Average time to complete Nine‐Hole Peg Test was slower than norms. Mean general conceptual ability composite scores from Differential Ability Scales Second Edition were very low ( M = 58.3, SD = 11.3). Fifty‐five percent of individuals had low adaptive functioning based on the Vineland Adaptive Behavioral Scales. Based upon the Child Behavior Checklist total problems score, the majority (65%) of individuals had behavioral challenges. The mean overall Quality of Life Inventory‐Disability score was 81.7 (SD = 11.9). These data provide a detailed characterization of clinical features in individuals with CTNNB1 neurodevelopmental disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Pediatrics, Pramongkutklao Hospital and Pramongkutklao College of Medicine, Bangkok, Thailand.
- Department of Pediatrics, Columbia University, New York, New York, USA.
- Department of Rehabilitation and Regenerative Medicine, Columbia University Irving Medical Center, New York, New York, USA.
- Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA.
- Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons and New York-Presbyterian Hospital, New York, New York, USA.
ORCID-Profile: Alison Garber, Jennifer M Bain
Förderung
- NICHD NIH HHS
- NIA NIH HHS
- CTNNB1 Connect and Cure
Zitieren
APA
Sudnawa, K. K., Garber, A., Cohen, R., Calamia, S., Kanner, C. H., Montes, J., Bain, J. M., Fee, R. J., & Chung, W. K. (2024). Clinical phenotypic spectrum of CTNNB1 neurodevelopmental disorder. Clinical Genetics, 105(5), 523-532. https://doi.org/10.1111/cge.14487
Vancouver
Sudnawa KK, Garber A, Cohen R, Calamia S, Kanner CH, Montes J, et al. Clinical phenotypic spectrum of CTNNB1 neurodevelopmental disorder. Clinical Genetics. 2024;105(5):523-532. doi:10.1111/cge.14487
BibTeX
@article{Sudnawa2024,
author = {Sudnawa, Khemika K and Garber, Alison and Cohen, Ryan and Calamia, Sean and Kanner, Cara H and Montes, Jacqueline and Bain, Jennifer M and Fee, Robert J and Chung, Wendy K},
title = {Clinical phenotypic spectrum of CTNNB1 neurodevelopmental disorder},
journal = {Clinical Genetics},
year = {2024},
volume = {105},
number = {5},
pages = {523--532},
doi = {10.1111/cge.14487}
}
EUVIMED